PosterPDF Available

Real-time seizure detection performance with Embrace alert system: One year real-life setting case study

Poster

Real-time seizure detection performance with Embrace alert system: One year real-life setting case study

Abstract

Monitoring of one patient with Embrace in real-life settings over 1 year
Real-time seizure detection performance with Embrace alert
system: one year real-life setting case study
G. Regalia1, C. Caborni1, M. Migliorini1, F. Onorati1, R. W. Picard1,2
1 Empatica Inc, Milan, Italy
2 MIT Media Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A
1st International congress on mobile health devices and seizure detection in epilepsy - Copenhagen 7-8 July 2017
Background
Automated mobile seizure detection devices can prompt caregivers
to intervene and provide objective seizure counts in daily life.
However, their performance outside epilepsy monitoring units (EMUs)
is largely unknown.
The Embrace system is the first commercially available multimodal
system combining accelerometer and electrodermal activity to detect
and alert to convulsive seizures (CSs) (Figure 1).
An automated machine-learning classifier was trained using video-
EEG labeled EMU data [1-3] and optimized using data from
outpatient settings [4].In aprior 3-month home study with one
patient and real-time detection and alerts, Embrace alerted to CS’s
with 92%sensitivity and less than 0.5 false alarms per day [5].
Here, we monitor apatient for 1year,and report the results.
Materials & Methods
A patient (age 15y) with Dravet Syndrome wore the Embrace smartwatch, which sent CS alerts to a smartphone for generating calls to
caregivers, and logged the calls and alerts time in an online database. The patient was never left alone and the patient’s caregivers were
asked to meticulously report each CS.
Two data experts independently inspected all the data to further verify the accuracy of caregivers’ self-reports.
Sensitivity was computed as the percentage of CSs that automatically triggered an alert. False alarms were counted by subtracting the
number of correctly recognized CSs from the total alerts.
Results Conclusions
For the first time, we have
tested the Embrace seizure
detection system during 1year
in real-life settings.
The performance is in the same
range as previous tests in best-
case clinical settings, i.e.
Sensitivity>95%and false alarm
rate<1alarm per day [6].
Similar longitudinal analysis on a
more heterogeneous patients’
population is underway.
Convulsive
seizure
detector
Accelerometers
Skin conductance
Embrace
Seizure
No seizure
On-wrist continuous
recordings
Alert generation and
transmission
Alert delivery to
caregivers
Figure 1.Top:Schematics of Embrace CS detection and alert system, composed
of awristband that detects an event, transmits an alert to his/her smartphone,
which generates acall via acloud-based service to designated caregivers.
Bottom:Detailed schematic workflow of the CS detector wristband.
Contacts
Giulia Regalia:
gr@empatica.com
Rosalind Picard:
rp@empatica.com
www.empatica.com/product-embrace
References
[1] Poh et al 2012, Epilepsia, 53(5),93-7
[2] Regalia et al 2015, American Epilepsy
Society meeting
[3] Onorati et al 2016, Epilepsy Pipeline
conference
[4] Onorati et al 2016, European Congress
on Epileptology
[5] Picard et al 2016, American Epilepsy
Society meeting
[6] Caborni et al 2016, Partners against
Mortality in Epilepsy conference
Figure 3.(A) Overview of Embrace outcome during the
monitoring period (one row = 1 day).Green:timing of the 45
detected seizures;purple:timing of the missed seizures;red:
timing of false alarms;dark blue:detected rest periods;light
blue:estimated rest period;gray:device off-wrist.
(B) Distribution of seizures (top) and false alarms (bottom)
wrt clock time.
Over aperiod of 11.3 months (341 days),
the patient wore Embrace 5,968 hours
(17.5±3.5 hours per day) and experienced
46 CSs.
Of the 46 CS’s, 45 produced real-time alerts
(Sensitivity=98%)(examples in Figure 2;
green ticks in Figure 3A).
All true positives were successfully
transmitted to the phone (mean delay=13
sec) and to the online database (mean
delay=16 sec).
The overall false alarm rate was 0.14 per
day worn (51 false alarms over the year;
red ticks in Figure 3A).
Zero false alarms were triggered during
rest periods (blue segments in Figure 3A).
Most days had zero false alarms (315 out of
341 days, i.e. 92%)
Figure 2.Example of electrodermal activity (EDA) and
acceleration (ACC) recorded by Embrace during two
convulsive seizures (left:detected;right:missed).
Orange bar refers to the detection time (left) or to the
seizure time reported by the patient (right).
0051
(A)
(B)
... Besides, there are several wearable devices that have been developed for seizure detection [9][10][11][12][13][14]. These devices use ECG [11], EMG [12] or body motion [10][11][12][13][14] to detect seizure. ...
... Besides, there are several wearable devices that have been developed for seizure detection [9][10][11][12][13][14]. These devices use ECG [11], EMG [12] or body motion [10][11][12][13][14] to detect seizure. However, for seizure detection, the EEG signals are the most direct bio-potential signal. ...
Article
Full-text available
In this paper, the design of a smart headband for epileptic seizure detection is presented. The proposed headband consists of four key components: 1) an analog front-end circuitry, 2) an epileptic seizure detection tag (ESDT), 3) a Bluetooth Low Power (BLE) chip, and 4) customized electrodes. All the above components are integrated into a fabric headband with only 50.3 g. The smart headband system dissipates 55.89 mW. The epileptic seizure detection algorithm inside ESDT is validated by using Boston Children’s Hospital’s CHB-MIT scalp EEG clinical database with the detection rate of 92.68% and the false alarm of 0.527/hour. We develop a service APP connected to the cloud so that the patients’ health condition can be recorded and then referenced by doctors for further diagnosis or research. CCBY
... Several ambulatory monitoring devices use physiological signal sources other than EEG including electrocardiogram 88 , electromyogram (EMG) 89 , body motion, 90,91 and electrodermal activity (EDA). 92,93 Innovative therapeutic interventions in the form of implantable devices in concert with AEEG coupled with drug and/or electrical stimulation promise the ability to predict, terminate, and provide treatment to patients with seizures in addition to activating emergency medical systems via smartphones and computer-based alerts. ...
Article
Full-text available
The COVID-19 pandemic forced temporary closure of epilepsy monitoring units across the globe due to potential hospital-based contagion. As COVID-19 exposures and deaths continues to surge in the United States and around the world, other types of long-term EEG monitoring have risen to fill the gap and minimize hospital exposure. AEEG has high yield compared to standard EEG. Prolonged audio-visual video-EEG capability can record events and epileptiform activity with quality like inpatient video-EEG monitoring. Technological advances in AEEG using miniaturized hardware and wireless secure transmission have evolved to small portable devices that are perfect for people forced to stay at home during the pandemic. Application of seizure detection algorithms and Cloud-based storage with real-time access provides connectivity to AEEG interpreters during prolonged “shut-down”. In this article we highlight the benefits of AEEG as an alternative to diagnostic inpatient VEM during the paradigm shift to mobile heath forced by the Coronavirus.
ResearchGate has not been able to resolve any references for this publication.